• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Holdings
Company Encyclopedia
View More
name
Tianhong Hang Seng Shanghai-Shenzhen-Hong Kong Innovative Drugs Selected 50 ETF
517380.SH
Shareholder
Ownership%OwnedShare ChgReport Date
No Data
News
View More

China’s new drug insurance: lifeline for patients or squeeze on big pharmaceutical firms?

China's new commercial insurance formulary for innovative drugs aims to make costly medicines like Leqembi and Kisunla more accessible and affordable for patients, including 17 million Alzheimer's sufferers. The scheme offers an alternative to the National Reimbursement Drug List (NRDL), allowing drug makers to enter China's vast market without deep price cuts. However, insurers may face financial challenges, and major state-owned enterprise insurers are advised not to participate in the pilot programme.

南华早报·12/17/2025 07:30
南华早报·12/17/2025 07:30

Hong Kong Stock Movement: ASCLETIS-B's buyback failed to boost confidence, with the stock price falling 11.02% against the trend

ASCLETIS-B fell 11.02%; CanSino Biologics fell 5.86%, with a transaction volume of HKD 937 million; BeiGene fell 7.15%, with a transaction volume of HKD 925 million; Innovent Biologics fell 3.99%, with a transaction volume of HKD 853 million; Kelun-Biotech fell 7.66%, with a market value of HKD 94 billion

HK Stock Movers Tracker·12/15/2025 13:51
HK
01672
+2.93%
HK Stock Movers Tracker·12/15/2025 13:51
HK
01672
+2.93%
© 2025 Longbridge|Disclaimer